Payment overview · 2025
General Payments
$221.27
13 reported records · 4 companies
Healthcare provider profile · identity verified
James Delbert Humphreys, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HOT SPRINGS, AR · NPI 1366403560
Verified facts
What the public records show
CMS Open Payments records show James Delbert Humphreys, M.D. received $221.27 in general payments during 2025 across 13 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 61.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $135.02 | 61.0% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.96 | 19.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.51 | 11.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.78 | 7.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $221.27 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $135.02 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.96 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $43.96 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.51 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
77 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
168 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
32 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 668 | 152 |
| Levothyroxine Sodium | Levothyroxine Sodium | 656 | 132 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 581 | 127 |
| Amlodipine Besylate | Amlodipine Besylate | 571 | 125 |
| Atorvastatin Calcium | Atorvastatin Calcium | 403 | 95 |
| Lisinopril | Lisinopril | 331 | 80 |
| Losartan Potassium | Losartan Potassium | 311 | 66 |
| Potassium Chloride | Potassium Chloride | 310 | 87 |
| Famotidine | Famotidine | 304 | 57 |
| Meloxicam | Meloxicam | 297 | 76 |
| Metformin Hcl | Metformin Hcl | 267 | 62 |
| Allopurinol | Allopurinol | 249 | 53 |
| Gabapentin | Gabapentin | 248 | 52 |
| Ezetimibe | Ezetimibe | 238 | 50 |
| Carvedilol | Carvedilol | 230 | 54 |
| Bupropion Xl | Bupropion Hcl | 223 | 41 |
| Furosemide | Furosemide | 223 | 61 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 221 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 44 |
| Ozempic | Semaglutide | 198 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 48 |
| Citalopram Hbr | Citalopram Hydrobromide | 194 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 188 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 179 | 48 |
| Omeprazole | Omeprazole | 169 | 34 |
| Eliquis | Apixaban | 168 | 32 |
| Alendronate Sodium | Alendronate Sodium | 162 | 36 |
| Simvastatin | Simvastatin | 159 | 33 |
| Temazepam | Temazepam | 159 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 156 | 36 |
| Methylprednisolone | Methylprednisolone | 153 | 121 |
| Trazodone Hcl | Trazodone Hcl | 145 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 28 |
| Nabumetone | Nabumetone | 135 | 32 |
| Donepezil Hcl | Donepezil Hcl | 132 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 130 | 101 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 113 | 81 |
| Warfarin Sodium | Warfarin Sodium | 112 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 110 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 25 |
| Tramadol Hcl | Tramadol Hcl | 109 | 28 |
| Sertraline Hcl | Sertraline Hcl | 98 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 97 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 97 | 23 |
| Finasteride | Finasteride | 95 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 86 | 22 |
| Alprazolam | Alprazolam | 85 | 14 |
| Glipizide Er | Glipizide | 84 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 33 |
| Atenolol | Atenolol | 81 | 21 |
| Montelukast Sodium | Montelukast Sodium | 81 | 23 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 77 | 11 |
| Synthroid | Levothyroxine Sodium | 77 | 17 |
| Sucralfate | Sucralfate | 74 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 26 |
| Celecoxib | Celecoxib | 71 | 15 |
| Gemfibrozil | Gemfibrozil | 69 | 15 |
| Sotalol | Sotalol Hcl | 67 | 18 |
| Spironolactone | Spironolactone | 67 | 14 |
| Primidone | Primidone | 63 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 39 |
| Fenofibrate | Fenofibrate | 61 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | suppressed |
| Clonazepam | Clonazepam | 59 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 59 | 14 |
| Levofloxacin | Levofloxacin | 58 | 50 |
| Valsartan | Valsartan | 58 | 12 |
| Farxiga | Dapagliflozin Propanediol | 57 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | 39 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 16 |
| Mounjaro | Tirzepatide | 52 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 48 | 13 |
| Mirtazapine | Mirtazapine | 47 | 18 |
| Ondansetron Odt | Ondansetron | 47 | 22 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 46 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 46 | 20 |
| Azithromycin | Azithromycin | 45 | 39 |
| Lorazepam | Lorazepam | 45 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Eszopiclone | Eszopiclone | 44 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Estradiol | Estradiol | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 38 | 35 |
| Methocarbamol | Methocarbamol | 38 | 21 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Naproxen | Naproxen | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 36 | 16 |
| Fluconazole | Fluconazole | 36 | 27 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 32 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Cefdinir | Cefdinir | 32 | 29 |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 32 |
| Prednisone | Prednisone | 32 | 14 |
| Cephalexin | Cephalexin | 31 | 27 |
| Bumetanide | Bumetanide | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 24 |
| Glipizide | Glipizide | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 24 |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 26 | 15 |
| Etodolac | Etodolac | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 14 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | 12 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $221.27 · 13 records | Otsuka America Pharmaceutical, Inc. | NURTEC ODT, OTEZLA, QULIPTA, REPATHA, REXULTI, UBRELVY, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error